{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:20:48Z","timestamp":1783405248485,"version":"3.54.6"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MIRAGE syndrome, a rare autosomal dominant disorder, is caused by heterozygous gain-of-function mutations in the SAMD9 gene. A key characteristic of MIRAGE syndrome is growth restriction. Although initially thought to stem mainly from prenatal and systemic factors, this growth restriction can also be a consequence of panhypopituitarism, leading to growth hormone deficiency (GHD). The use of recombinant human growth hormone (rhGH) to treat the characteristic severe growth failure is controversial due to an inherent risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report an 11-year-old male diagnosed with MIRAGE syndrome confirmed by a heterozygous\n                      <jats:italic>de novo<\/jats:italic>\n                      SAMD9 variant (c.4615T&amp;gt;A; p.Leu1539Ile) who had previously undergone allogeneic hematopoietic stem cell transplantation for MDS with monosomy 7. Severe pre- and postnatal growth restriction, characterized by short stature and slow growth velocity, marked the clinical course. Comprehensive hormonal testing was performed and ultimately revealed a growth hormone deficiency (GHD). At age 6, growth hormone therapy began after a brain MRI to assess the pituitary gland anatomy. This decision followed a comprehensive risk-benefit analysis and a hematological evaluation that showed no signs of clonal evolution. Over a six-year follow-up period, the patient demonstrated a significant improvement in growth velocity and height standard deviation score, with stable hematological parameters and no adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case expands the known endocrine phenotype of MIRAGE syndrome, providing the first report, to our knowledge, of a favorable and safe medium-term response to rhGH therapy in this condition. Our observations support systematic GH stimulation testing in MIRAGE patients with marked growth failure who survive beyond early childhood and suggest that, in carefully selected cases with proven GHD, rhGH replacement may be considered in close collaboration with hematology\/oncology teams and under strict hematological monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1885153","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:46:24Z","timestamp":1783403184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Growth hormone deficiency and response to treatment in MIRAGE syndrome: expanding the endocrine phenotype"],"prefix":"10.3389","volume":"17","author":[{"given":"Laura","family":"Trapani","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Trieste","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cognigni","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Trieste","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Maximova","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health IRCCS \u201cBurlo Garofolo\u201d","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Valencic","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health IRCCS \u201cBurlo Garofolo\u201d","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fachin","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health IRCCS \u201cBurlo Garofolo\u201d","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tamaro","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Trieste","place":["Trieste, Italy"]},{"name":"Institute for Maternal and Child Health IRCCS \u201cBurlo Garofolo\u201d","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Trieste","place":["Trieste, Italy"]},{"name":"Institute for Maternal and Child Health IRCCS \u201cBurlo Garofolo\u201d","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tornese","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Trieste","place":["Trieste, Italy"]},{"name":"Institute for Maternal and Child Health IRCCS \u201cBurlo Garofolo\u201d","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3569","article-title":"SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7","volume":"48","author":"Narumi","year":"2016","journal-title":"Nat Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/jci91913","article-title":"Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans","volume":"127","author":"Buonocore","year":"2017","journal-title":"J Clin Invest"},{"key":"B3","first-page":"1993","article-title":"MIRAGE syndrome","volume-title":"Genereviews\u00ae [Internet]","author":"Tanase-Nakao","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.953707","article-title":"Emerging phenotypes linked to variants in SAMD9 and MIRAGE syndrome","volume":"13","author":"Suntharalingham","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0074-4","article-title":"SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid Malignancies","volume":"32","author":"Davidsson","year":"2018","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02262-14","article-title":"SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses","volume":"89","author":"Liu","year":"2015","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121086","article-title":"Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes","volume":"3","author":"Wong","year":"2018","journal-title":"JCI Insight"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.142","article-title":"Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome","volume":"31","author":"Schwartz","year":"2017","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2024.104217","article-title":"Of gains and losses: SAMD9\/SAMD9L and monosomy 7 in myelodysplastic syndrome","volume":"134","author":"Cammenga","year":"2024","journal-title":"Exp Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-105020","article-title":"Two patients with MIRAGE syndrome lacking hematological features: role of somatic second-site reversion SAMD9 mutations","volume":"55","author":"Shima","year":"2018","journal-title":"J Med Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cge.13914","article-title":"Achalasia as a symptom guide in MIRAGE syndrome: A novel case with p.R1293Q and p.R902W variants in the SAMD9 gene","volume":"99","author":"Baquedano-Lobera","year":"2021","journal-title":"Clin Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.742495","article-title":"MIRAGE syndrome caused by a de novo c.3406G>C (p. Glu1136Gln) mutation in the SAMD9 gene presenting with neonatal adrenal insufficiency and recurrent intussusception: A case report","volume":"12","author":"Chin","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12882-020-02011-4","article-title":"A girl with MIRAGE syndrome who developed steroid-resistant nephrotic syndrome: A case report","volume":"21","author":"Ishiwa","year":"2020","journal-title":"BMC Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012682","article-title":"Poor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype","volume":"2","author":"Sarthy","year":"2018","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2020.06.002","article-title":"Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome","volume":"245","author":"Rentas","year":"2020","journal-title":"Cancer Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.28.147","article-title":"MIRAGE syndrome with recurrent pneumonia probably associated with gastroesophageal reflux and achalasia: A case report","volume":"28","author":"Yoshizaki","year":"2019","journal-title":"Clin Pediatr Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/0009922819832034","article-title":"Refractory infantile chronic diarrhea and failure to thrive in a 6-month-old boy with a complex past medical history","volume":"58","author":"Okafor","year":"2019","journal-title":"Clin Pediatr (Phila)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00625","article-title":"Reversion SAMD9 mutations modifying phenotypic expression of MIRAGE syndrome and allowing inheritance in a usually de novo disorder","volume":"10","author":"Roucher-Boulez","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0000000000002900","article-title":"Lacrimal gland hypoplasia and corneal anesthesia in MIRAGE syndrome","volume":"41","author":"Basilious","year":"2021","journal-title":"Cornea"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/TCRM.S294065","article-title":"Pediatric adrenal insufficiency: challenges and solutions","volume":"18","author":"Nistic\u00f2","year":"2022","journal-title":"Ther Clin Risk Manag"},{"key":"B21","unstructured":"Nieman\n              LK\n            \n            \n              Raff\n              H\n            \n            \n              DeSantis\n              A\n            \n          \n          Diagnosis of adrenal insufficiency in adults"},{"key":"B22","doi-asserted-by":"publisher","first-page":"103614","DOI":"10.1016\/j.ejmg.2019.01.004","article-title":"Pediatric endocrinology through syndromes","volume":"63","author":"Tornese","year":"2020","journal-title":"Eur J Med Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017717","article-title":"Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management","volume":"145","author":"Sahoo","year":"2025","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020538","article-title":"Emotional and behavioural adjustment in children and adolescents with short stature vs. Their normal-statured peers","volume":"14","author":"Guerrini Usubini","year":"2025","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ25-0656","article-title":"Long-term survival in MIRAGE syndrome: Insights into systemic manifestations and management with review of literature","author":"Yamada","year":"2026","journal-title":"Endocr J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1002","article-title":"Risk of neoplasia in pediatric patients receiving growth hormone therapy--A report from the pediatric endocrine society drug and therapeutics committee","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1885153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:46:35Z","timestamp":1783403195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1885153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":26,"alternative-id":["10.3389\/fendo.2026.1885153"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1885153","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1885153"}}